{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"MRCQPMQBCKEOCU-SAPNQHFASA-N","prefName":"EHP-102","symbol":"EHP-102","iupacName":"3-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(ethylamino)-4-hydroxy-6-pentylcyclohexa-3,5-diene-1,2-dione","aliases":["EHP-102","VCE-003.2"],"cas":null,"pubchemCid":"91864651","chebiId":null,"smiles":"CCCCCC1=C(C(=C(C(=O)C1=O)C/C=C(\\C)/CCC=C(C)C)O)NCC","molecularFormula":"C23H35NO3","molecularWeight":373.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/91864651"}},"classification":{"family":"semisynthetique","familyLabel":"Semi-synthetic cannabinoid","origin":"semisynthetic","originLabel":"Semi-synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Route of preparation (chemical process)","summaryFr":"No biosynthetic pathway: EHP-102 is not produced by any living organism. It derives from chemical synthesis, by oxidation of the cannabigerol ring to a quinone, then introduction of a nitrogen function. Only the class of transformation is described here.","originNote":"Semi-synthetic derivative of cannabigerol (CBG), the non-psychotropic hemp phytocannabinoid, itself chemically modified to obtain the molecule. No natural occurrence is reported in the sources consulted.","discovered":""},"pharmacology":{"summaryFr":"EHP-102, known in the scientific literature as VCE-003.2, is an aminoquinone derived from cannabigerol (CBG), obtained by chemical modification of the hemp molecule. Described in 2016 by the team of Díaz-Alonso, it has only negligible affinity for the CB1 and CB2 receptors (predicted Ki above 40 µM) and acts through PPARγ, a nuclear receptor involved in controlling inflammation, with an IC50 of 1.2 µM in a competitive binding assay. In mice, models of Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and synucleinopathy have been used to assess neuroprotective effects. The data are exclusively preclinical: no clinical trial is published in the sources consulted.","receptorSummaryFr":"In the published studies, EHP-102 has only negligible affinity for the CB1 and CB2 receptors: at 40 µM, radioligand displacement stays below 50% and the predicted Ki values are above 40 µM (García et al., 2018). Its documented activity goes through PPARγ, a nuclear receptor involved in controlling inflammation. It binds it with an IC50 of 1.2 µM in a competitive binding assay (Díaz-Alonso et al., 2016) and is described as a partial agonist of this receptor (Burgaz et al., 2024). A 2018 study points to a possible involvement of different binding sites on PPARγ (García et al., 2018). The sources consulted document no action on other targets of the endocannabinoid system.","binding":[{"target":"PPARγ","efficacy":"partial_agonist","relativeActivity":40,"reported":"IC50 1,2 µM en liaison compétitive (Díaz-Alonso et coll., 2016) ; agoniste partiel (Burgaz et coll., 2024)","confidence":"medium"}],"references":[{"label":"Díaz-Alonso et coll., VCE-003.2, nouveau dérivé du cannabigérol, favorise la survie des progéniteurs neuronaux et atténue la symptomatologie dans des modèles murins de maladie de Huntington, Scientific Reports 2016","pmid":"27430371","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/27430371/"},{"label":"García et coll., VCE-003.2, dérivé quinone du cannabigérol, dans un modèle de Parkinson induit par inflammation : sites de liaison possibles sur PPARγ, J Neuroinflammation 2018","pmid":"29338785","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/29338785/"},{"label":"Burgaz et coll., administration orale du VCE-003.2 contre la neurodégénérescence liée à l'inflammation dans la maladie de Parkinson expérimentale, Molecules 2019","pmid":"31349553","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/31349553/"},{"label":"Burgaz et coll., VCE-003.2 comme agent modificateur de la maladie dans un modèle murin de synucléinopathie, Behav Brain Funct 2024","pmid":"39487447","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/39487447/"},{"label":"Granja et coll., une quinone du cannabigérol atténue la neuro-inflammation dans un modèle chronique de sclérose en plaques, J Neuroimmune Pharmacol 2012","pmid":"22971837","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/22971837/"},{"label":"Rodríguez-Cueto et coll., effets neuroprotecteurs du VCE-003.2 chez des souris SOD1(G93A), modèle de sclérose latérale amyotrophique, Biochem Pharmacol 2018","pmid":"30076846","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/30076846/"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"ANSM, décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants (clause du noyau benzo[c]chromène)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-22-05-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"INCB, Green List 2026 (conventions de 1961 et 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem CID 91864651 : EHP-102 (identifiants)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/91864651"},{"label":"EHP-102, désignation et composé associé (repère tertiaire : Wikipédia)","pmid":null,"doi":null,"url":"https://en.wikipedia.org/wiki/EHP-102"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":2},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":2},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":2},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":2},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":2}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised control measure at European Union level is documented in the sources consulted for EHP-102, and the compound appears in no schedule of the 1971 Convention (INCB, Green List 2026). Any control therefore falls under national law. No marketing authorisation or novel food authorisation is documented.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Not classified to date. EHP-102 is not named in any annex of the order of 22 February 1990 or in the ANSM consolidated list (update of 16 February 2026). Its structure meets none of the generic definitions of that list: it has no indole, indazole, pyrrole, indene, cyclohexylphenol or thiazole core. It is not a tetrahydrocannabinol, and the benzo[c]chromene core clause of the decision of 22 May 2024 does not apply, as the molecule has no such ring. The absence of classification is not an authorisation: no marketing authorisation, as a medicine or as a novel food, is documented in the sources consulted.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Díaz-Alonso et coll., VCE-003.2, nouveau dérivé du cannabigérol, favorise la survie des progéniteurs neuronaux et atténue la symptomatologie dans des modèles murins de maladie de Huntington, Scientific Reports 2016","pmid":"27430371","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/27430371/"},{"label":"García et coll., VCE-003.2, dérivé quinone du cannabigérol, dans un modèle de Parkinson induit par inflammation : sites de liaison possibles sur PPARγ, J Neuroinflammation 2018","pmid":"29338785","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/29338785/"},{"label":"Burgaz et coll., administration orale du VCE-003.2 contre la neurodégénérescence liée à l'inflammation dans la maladie de Parkinson expérimentale, Molecules 2019","pmid":"31349553","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/31349553/"},{"label":"Burgaz et coll., VCE-003.2 comme agent modificateur de la maladie dans un modèle murin de synucléinopathie, Behav Brain Funct 2024","pmid":"39487447","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/39487447/"},{"label":"Granja et coll., une quinone du cannabigérol atténue la neuro-inflammation dans un modèle chronique de sclérose en plaques, J Neuroimmune Pharmacol 2012","pmid":"22971837","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/22971837/"},{"label":"Rodríguez-Cueto et coll., effets neuroprotecteurs du VCE-003.2 chez des souris SOD1(G93A), modèle de sclérose latérale amyotrophique, Biochem Pharmacol 2018","pmid":"30076846","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/30076846/"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"ANSM, décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants (clause du noyau benzo[c]chromène)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-22-05-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"INCB, Green List 2026 (conventions de 1961 et 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem CID 91864651 : EHP-102 (identifiants)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/91864651"},{"label":"EHP-102, désignation et composé associé (repère tertiaire : Wikipédia)","pmid":null,"doi":null,"url":"https://en.wikipedia.org/wiki/EHP-102"}],"meta":{"slug":"ehp-102","url":"https://en.phytogrammes.com/wiki/ehp-102","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-12","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}